Patheon Recognized for Most Effective Scale-Up and Technical Transfer at the European Outsourcing Awards

TORONTO, Canada, (October 2, 2008)  –  Patheon (TSX:PTI), a leading provider of contract development and manufacturing services to the global pharmaceutical industry, has won the European Outsourcing Award (EOA) in conjunction with Procter and Gamble Pharmaceuticals at this year’s event. Patheon has won in the category of the Most Effective Scale-Up and Technical Transfer award. This honor is in recognition of the impeccable work Patheon has provided with Procter and Gamble Pharmaceuticals. Their strategic partnership has been very successful and has demonstrated their effectiveness and reliability during a very demanding technical transfer.

Phill Slater, Director of External Supply Organization for Procter and Gamble stated, “Patheon was selected as our partner in this project based on their experience, capabilities in technology and quality management. With Patheon, we could ensure we met the needs of our customers now and in the future.”

Terry Novak, President of North America and Chief Marketing Officer, stated, “Patheon is proud to have won the Most Effective Scale-Up and Technical Transfer award at this year’s European Outsourcing Awards. Our performance in the industry is being recognized for a reason: we have dedicated ourselves to understanding our customer’s needs and developing both the capability and capacity to deliver on those needs. It’s rewarding to even be considered with Procter and Gamble for this award by other industry leaders.”

Launched in 2005, the European Outsourcing Awards recognizes significant developments in Contract Services and rewards successful companies for their outstanding contributions and achievements throughout the year. The awards were created to celebrate and recognize excellence in R&D, marketing, business, and technology across the pharmaceutical industry.  This year’s event took place in Frankfurt, Germany on October 1st, during the CPhI (Convention of Pharmaceutical Ingredients) trade show and conference.  Additional categories awarded include: Best New Product, Best Contract Manufacturing Project, and Most Outstanding Applications in Generics.

ABOUT PATHEON
Patheon Inc. (TSX:PTI; www.patheon.com) is a leading global provider of contract development and manufacturing services to the global pharmaceutical industry.  Patheon prides itself in providing the highest quality products and services to more than 300 of the world’s leading pharmaceutical and biotechnology companies. Patheon’s services range from preclinical development through commercial manufacturing of a full array of dosage forms including parenteral, solid, semi-solid and liquid forms.  Patheon uses many innovative technologies including single-use disposables, Liquid-Filled Hard Capsules and a variety of modified release technologies. 

Patheon’s comprehensive range of fully integrated Pharmaceutical Development Services includes pre-formulation, formulation, analytical development, clinical manufacturing, scale-up and commercialization.  Patheon can take customers direct to clinic with global clinical packaging and distribution services and Patheon’s Quick to Clinic™ programs can accelerate early phase development project to clinical trials while minimizing the consumption of valuable API.  Patheon’s integrated network strives to ensure that customer products can be launched with confidence globally.

Caution Concerning Forward-Looking Statements
This news release may contain forward-looking statements which reflect management’s expectations regarding the Company’s future growth of operations, performance (both operational and financial) and business prospects and opportunities.  These statements are made in the context of the risks and uncertainties that are outlined in the Company’s public documents, which can be accessed on our website at www.patheon.com or on SEDAR at www.sedar.com.

Contacts: